Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Top Cited Papers
- 30 November 2007
- journal article
- review article
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 21 (24) , 3214-3231
- https://doi.org/10.1101/gad.1609907
Abstract
In pugilistic parlance, the one-two punch is a devastating combination of blows, with the first punch setting the stage and the second delivering the knock-out. This analogy can be extended to molecularly targeted cancer therapies, with oncogene addiction serving to set the stage for tumor cell killing by a targeted therapeutic agent. While in vitro and in vivo examples abound documenting the existence of this phenomenon, the mechanistic underpinnings that govern oncogene addiction are just beginning to emerge. Our current inability to fully exploit this weakness of cancer cells stems from an incomplete understanding of oncogene addiction, which nonetheless represents one of the rare chinks in the formidable armor of cancer cells.Keywords
This publication has 202 references indexed in Scilit:
- Restoration of p53 function leads to tumour regression in vivoNature, 2007
- Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomasNature, 2007
- A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenesCancer Cell, 2006
- Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapyNature Clinical Practice Oncology, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Intrinsic tumour suppressionNature, 2004
- Cell Death: Critical Control PointsPublished by Elsevier ,2004
- Mutations of the BRAF gene in human cancerNature, 2002
- The Hallmarks of CancerCell, 2000
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993